NCT01913002CompletedPhase 1
Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Lexicon Pharmaceuticals
- Enrollment
- 63
- Locations
- 1
- Primary Endpoint
- Change from baseline in QTc intervals
Study Overview
Brief Summary
This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adult subjects ≥18 to ≤55 years of age
- •Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm
- •Body mass index (BMI) ≥18 and ≤35 kg/sq m
- •Able and willing to provide written informed consent
- •Nonsmoker and has not used any tobacco products for at least 3 months prior to Screening
- •Willing to adhere to the prohibitions and restrictions specified in this protocol
- •Able to tolerate prolonged periods of quiet, motionless, supervised rest
Exclusion Criteria
- •Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 5 days of dosing
- •Use of any investigational agent or study treatment within 30 days prior to Screening
- •Use of any protein or antibody-based therapeutic agents within 3 months prior to Screening
- •Prior exposure to LX4211
- •Daily use of cigarettes or any tobacco products within 3 months prior to Screening and while participating in the study
- •History of any major surgery within 6 months prior to Screening
- •History of any serious adverse reaction or hypersensitivity to any inactive component of LX4211
- •History of renal disease or significantly abnormal kidney function tests
- •History of hepatic disease or significantly abnormal liver function tests
- •Women who are breastfeeding or are planning to become pregnant during the study
- •History of any active infection within 14 days prior to Screening
- •History of alcohol or substance abuse within 2 years prior to Screening
- •History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2
- •Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF >450 msec for females and QTcF >430 msec for males) at Screening
- •>30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of Period 1
- •History of additional risk factors for the presence of a family history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young age (<=40 years), drowning or sudden infant death syndrome in a first degree relative (ie, biological parent, sibling, or child)
- •Any skin condition likely to interfere with ECG electrode placement or adhesion
- •Any skin condition likely to interfere with ECG electrode placement or adhesion
- •Donation or loss of >400 mL of blood or blood product within 3 months prior to Screening
- •Positive urine glucose during Screening
- •Positive pregnancy test during Screening
- •Positive urine screen for drugs of abuse during Screening
- •Positive urine test for alcohol during Screening
- •Inability or difficulty swallowing whole tablets or capsules
- •Unable or unwilling to communicate or cooperate with the Investigator for any reason
Arms & Interventions
Treatment A
Experimental
LX4211 800 mg
Intervention: LX4211 Placebo (Drug)
Treatment D
Placebo Comparator
Placebo
Intervention: LX4211 2000 mg (Drug)
Treatment D
Placebo Comparator
Placebo
Intervention: moxifloxacin 400 mg (Drug)
Treatment A
Experimental
LX4211 800 mg
Intervention: LX4211 800 mg (Drug)
Treatment A
Experimental
LX4211 800 mg
Intervention: LX4211 2000 mg (Drug)
Treatment A
Experimental
LX4211 800 mg
Intervention: moxifloxacin 400 mg (Drug)
Treatment B
Experimental
LX4211 2000 mg
Intervention: LX4211 800 mg (Drug)
Treatment B
Experimental
LX4211 2000 mg
Intervention: LX4211 2000 mg (Drug)
Treatment B
Experimental
LX4211 2000 mg
Intervention: moxifloxacin 400 mg (Drug)
Treatment B
Experimental
LX4211 2000 mg
Intervention: LX4211 Placebo (Drug)
Treatment C
Active Comparator
moxifloxacin 400 mg
Intervention: LX4211 800 mg (Drug)
Treatment C
Active Comparator
moxifloxacin 400 mg
Intervention: LX4211 2000 mg (Drug)
Treatment C
Active Comparator
moxifloxacin 400 mg
Intervention: moxifloxacin 400 mg (Drug)
Treatment C
Active Comparator
moxifloxacin 400 mg
Intervention: LX4211 Placebo (Drug)
Treatment D
Placebo Comparator
Placebo
Intervention: LX4211 800 mg (Drug)
Treatment D
Placebo Comparator
Placebo
Intervention: LX4211 Placebo (Drug)
Outcomes
Primary Outcomes
Change from baseline in QTc intervals
Time Frame: Day -1, Day 1 of each period (2, 3, 4)
Secondary Outcomes
- Plasma concentrations of LX4211(Day 1 of each Period: predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 60 hours after dosing time on Day 1 hours)
- Number of subjects experiencing an adverse event(up to 87 days)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study of LX4211 in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00962065Lexicon Pharmaceuticals36
Completed
Phase 3
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-UveitisUveitis, PosteriorUveitis, IntermediatePanuveitisNCT00404612Lux Biosciences, Inc.218
Completed
Phase 3
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior UveitisUveitis, AnteriorPanuveitisNCT00404885Lux Biosciences, Inc.108
Completed
Phase 1
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 DiabeticsType 2 Diabetes MellitusNCT01441232Lexicon Pharmaceuticals18
Completed
Phase 3
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-UveitisUveitis, PosteriorUveitis, IntermediatePanuveitisNCT00404742Lux Biosciences, Inc.232